Spoken Alpha
BRISTOL MYERS SQUIBB CO
Bristol Myers Squibb manufactures and sells pharmaceutical products for oncology, immunology, cardiovascular disease, and cell therapy, primarily to hospitals, healthcare providers, and patients through wholesalers and direct distribution channels.
BRISTOL MYERS SQUIBB CO is a Healthcare company operating in Drug Manufacturers - General with a $127.71B market cap.
Most recent reported earnings: Q3 FY2026 (Oct 28, 2026).
23 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-10-04.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BMY.
$ curl https://api.spokenalpha.com/v1/companies/BMYFAQ
Spoken Alpha indexes BMY's earnings call transcripts at https://spokenalpha.com/companies/BMY. Each call links to attributed speakers and parsed analyst Q&A. BRISTOL MYERS SQUIBB CO's own investor relations page is at https://www.bms.com/investors.html.
BRISTOL MYERS SQUIBB CO (BMY) held its most recent earnings call on 2026-10-29, covering fiscal Q3 2026.
BRISTOL MYERS SQUIBB CO (BMY) operates in the Healthcare sector (Drug Manufacturers - General industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-28 | — | $1.68 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-29 | $2.04 | $1.59 | +28.3% | $12.97B | — | — | EODHD |
| Q1 FY2026 | 2026-04-29 | $1.58 | $1.42 | +11.3% | $11.49B | — | — | EODHD |
| Q4 FY2025 | 2026-02-04 | $1.26 | $1.20 | +5.0% | $12.50B | — | — | EODHD |
| Q3 FY2025 | 2025-10-29 | $1.63 | $1.52 | +7.2% | $12.22B | — | — | EODHD |
| Q2 FY2025 | 2025-07-30 | $1.46 | $1.10 | +32.7% | $12.27B | — | — | EODHD |
| Q1 FY2025 | 2025-04-23 | $1.80 | $1.50 | +20.0% | $11.20B | — | — | EODHD |
| Q4 FY2024 | 2025-02-05 | $1.67 | $1.47 | +13.6% | $12.34B | — | — | EODHD |
| Q3 FY2024 | 2024-10-30 | $1.80 | $1.50 | +20.0% | $11.89B | — | — | EODHD |
| Q2 FY2024 | 2024-07-25 | $2.07 | $1.63 | +27.0% | $12.20B | — | — | EODHD |
| Q1 FY2024 | 2024-04-24 | $-4.40 | $-4.14 | -6.3% | $11.87B | — | — | EODHD |
| Q4 FY2023 | 2024-02-01 | $1.59 | $1.43 | +11.2% | $11.48B | — | — | EODHD |
| Q3 FY2023 | 2023-10-25 | $2.00 | $1.77 | +13.0% | $10.97B | — | — | EODHD |
| Q2 FY2023 | 2023-07-26 | $1.75 | $1.99 | -12.1% | $11.23B | — | — | EODHD |
| Q1 FY2023 | 2023-04-26 | $2.05 | $1.97 | +4.1% | $11.34B | — | — | EODHD |
| Q4 FY2022 | 2023-02-01 | $1.82 | $1.73 | +5.2% | $11.41B | — | — | EODHD |
| Q3 FY2022 | 2022-10-24 | $1.99 | $1.83 | +8.7% | $11.22B | — | — | EODHD |
| Q2 FY2022 | 2022-07-26 | $1.93 | $1.80 | +7.2% | $11.89B | — | — | EODHD |
| Q1 FY2022 | 2022-04-28 | $1.96 | $1.90 | +3.2% | $11.65B | — | — | EODHD |
| Q4 FY2021 | 2022-02-03 | $1.83 | $1.80 | +1.7% | $11.98B | — | — | EODHD |
Source: EODHD. BMY reported actuals as published; sparse fields render as —.